Phase 1 N=15 Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis
Pulmonary Sarcoidosis · Lung Function
Primary: Change in Absolute FVC From Baseline to Post Completion of 8 Weeks of Antibiotic Therapy. — 2.61 liters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Trial of Antimycobacterial Therapy in Sarcoidosis
Sarcoidosis
Primary: Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions — -8.4…
Phase 2 N=50 Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study
Sarcoidosis
Primary: Forced Vital Capacity (FVC) — 0.07; -0.07 liters
Phase 2 N=17 Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis
Cardiac Sarcoidosis
Primary: Change in Inflammation Marker — -43; 7 mg/L
Phase 2 N=40 Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Change Between Baseline and Week 24 in Pulmonary Function as Measured by Spirometry — -1.90; 0.52 Percent Predicted Forced Vital Capacity
Phase 2 N=15 Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
Sarcoidosis
Primary: Number of Participants Without Sarcoidosis Flare (Flare-Free Survival) — 2; 7 Participants
Phase 2 N=173 A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
Sarcoidosis
Primary: Change From Baseline in Percent-predicted Forced Vital Capacity (FVC) at Week 16 — 2.02; 1.15; -0.15 percent of predicted FVC — p=0.543
Phase 2 N=55 Atorvastatin to Treat Pulmonary Sarcoidosis
Sarcoidosis, Pulmonary
Primary: The Steroid Sparing Period — 301; 257 days
Phase 3 N=12 Tadalafil for Sarcoidosis Associated Pulmonary Hypertension
Pulmonary Hypertension
Primary: 6 Minute Walk Distance — 419.1; 418.1; 436.5; 377.1 meters — p=0.68
N/A N=17 The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Bronchoalveolar Lavage (BAL) and Peripheral Blood Mononuclear Cells (PBMC) TNF-α Levels — 40767; 39938; 45176; 25671 pg/ml
Phase 2 N=97 Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
Sarcoidosis; Antimycobacterial Therapy
Primary: Change in Percent Predicted Absolute Forced Vital Capacity (FVC) in Participants With Pulmonary Sarcoidosis, Comparing Baseline With Performance After Completion of 16…
Phase 4 N=4 Treatment of CNS Sarcoidosis With H.P. Acthar Gel
CNS Sarcoidosis
Primary: Karnofsky Performance Status (KPS) Score — 76.67; 76.67 score on a scale — p=1.0
Phase 1 N=5 Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
Sarcoidosis, Pulmonary · Sarcoidosis Lung · Sarcoidosis
Primary: Number of Participants With 50% Reduction in Corticosteroid Requirement — 3 Participants
N/A N=9 Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
Ocular Sarcoidosis · Panuveitis · Anterior Uveitis
Primary: Percentage of Patients With Clinically Significant Improvement in Visual Acuity — 3 Participants
Phase 2 N=62 Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Change in Percent Predicted FVC From Baseline to 16 Weeks of Treatment — -0.48; 1.02 Percent predicted — p=0.1804
Phase 4 N=55 Acthar Gel in Participants With Pulmonary Sarcoidosis
Sarcoidosis, Pulmonary
Primary: DBT: Number of Participants in Each Category of Assessment Based on Forced Vital Capacity (FVC), a Pulmonary Function Test Parameter at Week 24 — 10; 7; 12; 12…
N/A N=17 Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
Sarcoidosis
Primary: Number of Participants Characterized by Abnormal or Negative Uptake — 4; 3; 6 Participants
Phase 2 N=64 Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
Neuropathy of Sarcoidosis
Primary: Change in Corneal Nerve Fiber Area — -64.3; 533.8; 203.8; -170.0 µm^2
Phase 4 N=15 d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis
Cardiac Sarcoidosis
Primary: 68Ga-DOTATATE Uptake With Cardia Sarcoidosis (CS)
Phase 2 N=142 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Phase 2 N=37 Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
Pulmonary Sarcoidosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 10; 8; 7; 8 Participants
Phase 2 N=12 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
N/A N=50 SPARC Smartphone Application for the Management of Sarcoidosis-Associated Fatigue
Sarcoidosis · Fatigue
Primary: Proportion of Participants Recruited — 25; 25 Participants
Phase 3 N=158 Scleroderma Lung Disease
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
Phase 2 N=19 IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Phase 3 N=6 High Dose Cyclophosphamide for Treatment of Scleroderma
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
N/A N=80 Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary: Death From All Causes — 10; 5 Participants
Phase 2 N=51 Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
Scleroderma, Systemic · Interstitial Lung Disease
Primary: Percent Predicted Forced Vital Capacity (FVC-%) — 2.24; 2.09 percent predicted — p=0.9326
Phase 2 N=97 Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Systemic Sclerosis
Primary: Change From Baseline in Modified Rodnan Skin Score to Week 24 — -2.45; -4.76 score on a scale — p=0.0291
Phase 2 N=9 Imatinib in Systemic Sclerosis
Scleroderma, Systemic
Primary: Percent Change in Modified Rodnan Skin Score at 6 Months Compared to Baseline — -32 percentage of change in MRSS — p=0.005